CytoSorbents Announces 2020 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Cytosorbents (CTSO) Reports Q4 Revenues Beat
March 9, 2021 4:21 PM ESTCytosorbents (NASDAQ: CTSO) reported Q4 revenue for the quarter came in at $12 million versus the consensus estimate of $10.95 million.
Q4 2020 Results
Q4 2020 total revenue was approximately $12.0 million versus $7.4 million a year agoProduct sales growth accelerated in Q4 2020, with record quarterly product sales of approximately $11.5 million, a 74% increase from $6.6 million in Q4 2019Product gross margins were a record high of 82% in Q4 2020 versus 80% in Q4 2019Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, "In our recent stockholder letter, I discussed how the company successfully navigated a... More
